RDIF brings together the best Russian and international technologies in the fight against COVID-19
Production of the first registered COVID-19 vaccine in the world
The Sputnik V vaccine, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against coronavirus.
Sputnik V is based on a safe and tested human adenovirus vector platform. Using two different human adenoviral vectors is a unique approach that allows to boost the immune response and provide long lasting immunity.
The efficacy of the Sputnik V vaccine is confirmed at 91.6% based on the analysis of data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.
RDIF jointly with partners and manufacturers is ramping up the production of Sputnik V. The lyophilized (dry) form of the vaccine can be stored at a temperature of +2 to +8 degrees Celsius, which allows for easy distribution worldwide, including hard-to-reach regions.
The vaccine supplies for the global market will be produced by RDIF’s international partners in India, Brazil, China, South Korea and other countries.
After the Sputnik V vaccine’s clinical trial preliminary results showed its efficacy at above 90 percent, the Russian Direct Investment Fund and Gamaleya Institute on November 23, 2020 offered AstraZeneca to use one of the two components (human adenoviral vectors) of the Sputnik V vaccine in AstraZeneca’s clinical trials.
AstraZeneca accepted RDIF’s proposal and began clinical trials of its vaccine in combination with Sputnik V’s human adenoviral vector type Ad26. This research will allow AstraZeneca’s scientists to study the possibility of boosting their vaccine’s efficacy through the application of this combined approach.
For more information visit sputnikvaccine.com and follow Sputnik V on social networks.